Sistema Integrado de Información de la Protección Social - Integrated Social Protection Information System (SISPRO) (Colombia)

Field Names
Records
Coordinating Country
Colombia
Region

Colombia

Brief Database Description

SISPRO (Sistema Integrado de Información de la Protección Social - Integrated Social Protection Information System) comprises:
- Administrative registries,
- Population and Special population censuses,
- Surveys, and
- Geographical & Population studies.

SISPRO began in 1979, when the Ministry of Health defined standards for responsibilities, classification of information, periodicity of reports, clarity, and destinations for epidemiological information collected by healthcare providers in Colombia. However, it was not until 2001 that the Ministry defined the system’s design, regulations, and implementation. In 2007, the acronym SISPRO officially appeared for the first time in a ministerial act, and the Ministry of Health, solely responsible for administering the system information. In 2011, SISPRO was formally deployed online. The SISPRO database allows users, even those with no expertise in data analysis, to perform their own basic data queries. Raw data are analyzed by directly accessing information cubes, which allow the use of queries to export requested data.

SISPRO has several databases, but as of now only the following two are the most used ones. (The other databases have passed through many changes, upgrades and consistency validations over recent years, so those data are not very reliable. Finally, the following two are the ones that are more validated and being used for now.) 
Two of the most-used SISPRO research databases include: 
1) SISMED (El Sistema de Información de Precios de Medicamentos): Data based on the reports of manufacturers to the Government, it includes sales in units and values for all the medicines distributed in the country (Retail Channel and Institutional Channel).
2) MIPRES (My Prescription - Mipres – for the acronym in Spanish): Prescription data of specialty care reimbursed products in Colombia; the government centralizes it.

NOTE: While data have been around for a longer period, data are most reliable since the year 2018 because prior to that the data had many errors and problems, and most of the manufacturers did not report back then.

Database Type
Longitudinal Population Database

[1) SISMED:
Longitudinal Population Database - Drug data only, including all channels and reported by manufacturers, Sales data reports, units and values per SKU/Product/Manufacturer at Country Level. Note: In future it will be reported by regions.

2) MIPRES:
Longitudinal Population Database -
Drug and Diagnosis Data
Medical and Pharmacy Insurance
Outpatient and inpatient]

Database Source
Medical Insurance Claims
Other

[1) SISMED: Government requested data to manufacturers
2) MIPRES: Government Medical Insurance Claims]

Frequency of Data Collection
Monthly
Frequency of Data Update
Quarterly
Years Covered
2018 - Present

NOTE: While data have been around for a longer period, data are most reliable since the year 2018 because prior to that the data had many errors and problems, and most of the manufacturers did not report back then.

Population Type
General Population
Outpatient/Non-Institutionalized
Inpatient
Patient Type
Inpatient and Outpatient
Emergency Room (ER/ED)
Date of Last Update
Ongoing

SISPRO is updated on an ongoing (quarterly) basis.
This profile was developed for the B.R.I.D.G.E. TO DATA site on January 24, 2024.

Field Names
Records
Database Population Size
20 - 50 Million

(~49 Million, i.e., 95% of the country's population)

Active Population Size
20 - 50 Million

(~49 Million, i.e., 95% of the country's population)

Annual Change in Population
It is estimated that approximately 700,000 people are added to health coverage annually and this database includes them.
Sample Weights - Extrapolation Factors
No
Final Population Size
N/A

(Not applicable as data are still being collected)

Field Names
Records
Age of Patients at Data Collection
Yes
Approximate Percentage of Participants <18 years and those >65 years

N/A

(Information is not available to us; please contact database manager for information)

Gender Data
Yes
Percentage of Males/Females

N/A

(Information is not available to us; please contact database manager for information)

Ethnicity / Race Data
N/A

(Information is not available to us; please contact database manager for information)

Geographic Location

Colombia

Date of Birth Recorded
N/A

(Information is not available to us; please contact database manager for information)

Death Recorded
N/A

(Information is not available to us; please contact database manager for information)

Availability of death certificate / autopsy information
N/A

(Information is not available to us; please contact database manager for information)

Other Demographic Data
N/A

(Not applicable)

Field Names
Records
Physician ID
Yes

(Only for MIPRES database)

Physician Specialty
Yes

(Only for MIPRES database)

Pharmacy ID
N/A

(Not applicable)

Field Names
Records
Diagnosis Data
Yes

Diagnosis data are only available for the MIPRES database

Diagnoses Coded
ICD-10
Diagnoses: Date Parameters
2018 - Present

NOTE: While data have been around for a longer period, data are most reliable since the year 2018 because prior to that the data had many errors and problems, and most of the manufacturers did not report back then.

Diagnoses: Maximum Number of Codes Allowed
Unlimited
Physical Examination Findings
N/A

(Not applicable)

Birth Defect Data
N/A

(Not applicable)

Cancer Data
Yes

Please contact database manager for details

Infectious Disease Data
Yes

Please contact database manager for details

Environmental Exposures
No
Behavioral Data Elements
No
Field Names
Records
Procedure Data
N/A

(Not applicable)

Procedures Coded
N/A

(Not applicable)

Number of Procedures Coded
N/A

(Not applicable)

Procedure Date Parameters
N/A

(Not applicable)

Laboratory Information
N/A

(Not applicable)

Field Names
Records
Drug Data
Yes

[1) SISMED: Prescription & OTC
2) MIPRES: Prescription only]

Drug Date Parameters
2018 - Present

NOTE: While data have been around for a longer period, data are most reliable since the year 2018 because prior to that the data had many errors and problems, and most of the manufacturers did not report back then.

Drug Regimen & Route
Yes

Information is available on how the drug is administered, but not the frequency of administration

Drug Manufacturer
Yes

Information is available on the laboratory/corporation (manufacturer)

Drug Dosage
Yes

Details are available on the concentration of each SKU

Drug Days Supply
No
Drug Coding System: Maximum Number
Unlimited
Drug Coding System: Primary
Other

[CUP - In Colombia, health services have a unique code known as Clasificación Única de Procedimientos en Salud (CUP; Unique Classification of Health Procedures). CUP corresponds to a logical and detailed ordering of the procedures and interventions important for the standardization and billing of medical services for several reasons. CUP codes are identified by a code and described by a validated nomenclature. This classification is organized into sections, groups, subgroups, categories and subcategories. It is applicable for surgical and non-surgical procedures and interventions, on the community, its environment and health, and towards the protection of the health of workers.

CUM - In Colombia, medications have unique codes per product known as Código Único de Medicamento (CUM; Unique Medication Code). The CUM identifies individual commercial products, so there could be several CUM codes with the same Anatomical Therapeutic Chemical Code – Chemical substance level (ATC5) which identifies the active principle of a medication. A CUM code is the alphanumeric identification assigned to medications by the National Institute for Drug and Food Surveillance (INVIMA). The CUM is made up of the tracer number, which will allow the other components of the code to be related, such as:
- ATC- Classification system, chemical, anatomical, therapeutic
- INN: International Common Name
- Pharmaceutical form
- Composition
- Route of administration
- Description commercial presentation
- Tracer number: file number of the medicine under which the health registration application was processed, followed by a consecutive number assigned by INVIMA to each commercial presentation, which is part of the CUM and will be mandatory for those who must report. drug prices.]

Drug Coding System: Other
Other

[IUM (The Unique Medication Identifier).

According to the English translations of various ANVISA resolutions and the GS1 Healthcare Q&A with ANVISA from last year, the IUM is a secondary product code and comprises (this specific order when printed in human readable on the drug label):
- The ANVISA medication registry number for the drug;
- This 13-digit code is comparable to the NDC in the US;
- A serial number: This must be 13 digits chosen by the manufacturer and must be unique to the specific package it is printed on and unique across all products marketed by that manufacturer. This is different from the definition of a GS1 serial number because it is not tied to a specific Global Trade Item Number (GTIN) or even the medication registry number;
- The expiration date of the drug - When printed in human readable form, this must appear as “MM/YY”; and
- The lot/batch number of the product - This may be up to 20 alphanumeric characters and is assigned by the manufacturer.]

Drug Generic Name
Yes

Information is provided on the name of the molecule, concentration, and the manufacturer for each generic product.

Drug Additional Information
Yes

The main data are units and values, but there is also product type and therapeutic classification.

Field Names
Records
Biobank Type
N/A
Human Specimen
N/A
Blood Type
N/A
Biomarkers
N/A
Patient ID
N/A
Number of Samples
N/A
Frequency of Sample Collection
N/A
Pre-diagnostic Sample Collection
N/A
Post-treatment Sample Collection
N/A
Method of Sample Collection
N/A
Age at Sample Collection
N/A
Date of Sample Collection
N/A
Reason for Sample Collection
N/A
Method of Sample Storage
N/A
Length of Sample Storage
N/A
Pathology
N/A
DNA Isolation
N/A
RNA Isolation
N/A
Cell Culture
N/A
Genetic Testing
N/A
Access for Research: Specimens
N/A
Access for Research: Genetic Data
N/A
Access for Research: Epidemiologic Data
N/A
Quality Assurance Procedures
N/A
Family History
N/A
Medical History
N/A
Biobank Linkage
N/A
Field Names
Records
Type of Genetic Database
N/A
Source of Genetic Data
N/A
Specimen Genotyped
N/A
Tissue Form
N/A
Genetic Template
N/A
Gene-Drug Response
N/A
Gene-Disease Relationship
N/A
Gene-Health Outcome Relationship
N/A
Gene-Environment Response
N/A
Method of Imputing Genetic Data
N/A
Genetic Variant Identification
N/A
Genetic Data Level
N/A
Genotyping Method
N/A
Method of Genetic Variant Filtering
N/A
Haplotypes
N/A
Haplogroups
N/A
Variable Number of Tandem Repeats (VNTR)
N/A
Single Nucleotide Polymorphisms (SNPs)
N/A
Variant Type
N/A
Variant Class
N/A
Mutation Indicated
N/A
Position
N/A
Amino Acid Change
N/A
Genotype / Polymorphism
N/A
Allele Frequency
N/A
Linkage Disequilibrium (r²)
N/A
Noncarriers Indicated
N/A
Association Statistics
N/A
Genetic Relatedness Pairing
N/A
Data Sharing: Genetic Data
N/A
Access for Research
N/A
Genetic Data Linkage
N/A
Description of Genetic Data Linkage
N/A
Field Names
Records
Cost Data
Yes
Cost Denomination
United States Dollar (USD)

[Also Colombian Peso (COP)]

Type of Cost Data
Yes

(Actual Wholesale)

Surrogate Cost Data Link
N/A

(Not applicable)

Description of Surrogate Link
N/A

(Not applicable)

Field Names
Records
Data Validation Against Original Source
Yes

Retail data are validated with direct information from wholesalers of the pharmacies

Access to Medical Records
No
Linkage to Other Databases
Yes
Brief Description of Linkage Capabilities

Linkage is possible to Close-Up Sales Data and Prescription data of Retail Market

Please contact database manager for more information

Field Names
Records
Database Contact Data

Guilherme Alfano
Close-Up 
Email: galfano@closeupus.com

NOTE: Close-Up has access rights to officially receive and process SISPRO data; it is not open to the general public.

Website
https://www.close-upinternational.com/
Alternate Contact

Email: support@close-upinternational.com

Source of Database Funding
Government
Sponsoring Government Agency
Government of Colombia
Sponsoring Pharmaceutical Manufacturer

N/A

(Not applicable)

Database Usage Restrictions
Private Access

The general public cannot access the database. For information regarding data access, please contact the database manager.

Charge for Database Usage
No
Data Media Format
FLAT files

Power BI files

Number of Publications Using Database
>10
References of Studies Using/Describing Database

1. Florez-Esparza G, Cifuentes-González C, Rojas-Carabali W, Mejía-Salgado G, Pineda-Sierra JS, Pardo-Pizza D, Lesley Cruz D, de-la-Torre A. Colombian Ocular Inflammatory Diseases Epidemiology Study (COIDES): Prevalence, Incidence, and Sociodemographic Characterization of Uveitis in Colombia, 2015-2020. Ocul Immunol Inflamm. 2023 Nov 16:1-7.

2. Camero G, Villamizar G, Pombo LM, Saba M, Frank AL, Teherán AA, Acero GM. Epidemiology of Asbestosis between 2010-2014 and 2015-2019 Periods in Colombia: Descriptive Study. Ann Glob Health. 2023 Aug 22;89(1):54.

3. Londoño AM, Castro-Ayarza JR, Kronfly A, Buitrago DC, Samacá DF. Epidemiology and healthcare resource utilization in atopic dermatitis in Colombia: A retrospective analysis of data from the National Health Registry from 2015 to 2020. Biomedica. 2023 Mar 30;43(1):107-120.

4. Waich A, Ruiz Severiche J, Manrique Andrade M, Castañeda Aza JA, Castellanos Ramírez JC, Otero Mendoza L, Restrepo Gualteros SM, Panqueva OP, Hidalgo Martínez P. Prevalence of sleep apnea in children and adolescents in Colombia according to the national health registry 2017-2021. PLoS One. 2022 Aug 31;17(8):e0273324.

5. Fernández-Ávila DG, Bernal-Macías S, Parra MJ, Rincón DN, Gutiérrez JM, Rosselli D. Prevalence of osteoporosis in Colombia: Data from the National Health Registry from 2012 to 2018. Reumatol Clin (Engl Ed). 2021 Dec;17(10):570-574.

6. Cifuentes-González C, Amaris-Martínez S, Reyes-Guanes J, Uribe-Reina P, de-la-Torre A. Incidence, prevalence, and demographic characteristics of ocular cicatricial pemphigoid in Colombia: data from the National Health Registry 2009-2019. Int J Ophthalmol. 2021 Nov 18;14(11):1765-1770.

7. Fernández-Ávila DG, Bernal-Macías S, Gutiérrez JM, Rincón DN, Rosselli D. Prevalence of systemic sclerosis in Colombia: Data from the National Health Registry 2012-2016. J Scleroderma Relat Disord. 2020 Jun;5(2):137-142.

8. León-Núñez LJ, Camero-Ramos G, Gutiérrez JM. Epidemiology of snakebites in Colombia (2008-2016). Rev Salud Publica (Bogota). 2020 May 1;22(3):280-287.

9. Fernández-Ávila DG, Bernal-Macías S, Rincón-Riaño DN, Gutiérrez Dávila JM, Rosselli D. Prevalence of systemic lupus erythematosus in Colombia: data from the national health registry 2012-2016. Lupus. 2019 Sep;28(10):1273-1278.

10. Fernández-Ávila DG, Bernal-Macías S, Rincón-Riaño DN, Gutiérrez JM, Rosselli D. Prevalence of polymyalgia rheumatica in Colombia: data from the national health registry 2012-2016. Rheumatol Int. 2019 Sep;39(9):1631-1635. 

Database Contact
Database Contact Data

Guilherme Alfano
Close-Up 
Email: galfano@closeupus.com

Alternate Contact

Email: support@close-upinternational.com

References of Studies Using/Describing Database

1. Florez-Esparza G, Cifuentes-González C, Rojas-Carabali W, Mejía-Salgado G, Pineda-Sierra JS, Pardo-Pizza D, Lesley Cruz D, de-la-Torre A. Colombian Ocular Inflammatory Diseases Epidemiology Study (COIDES): Prevalence, Incidence, and Sociodemographic Characterization of Uveitis in Colombia, 2015-2020. Ocul Immunol Inflamm. 2023 Nov 16:1-7.

2. Camero G, Villamizar G, Pombo LM, Saba M, Frank AL, Teherán AA, Acero GM. Epidemiology of Asbestosis between 2010-2014 and 2015-2019 Periods in Colombia: Descriptive Study. Ann Glob Health. 2023 Aug 22;89(1):54.

3. Londoño AM, Castro-Ayarza JR, Kronfly A, Buitrago DC, Samacá DF. Epidemiology and healthcare resource utilization in atopic dermatitis in Colombia: A retrospective analysis of data from the National Health Registry from 2015 to 2020. Biomedica. 2023 Mar 30;43(1):107-120.

4. Waich A, Ruiz Severiche J, Manrique Andrade M, Castañeda Aza JA, Castellanos Ramírez JC, Otero Mendoza L, Restrepo Gualteros SM, Panqueva OP, Hidalgo Martínez P. Prevalence of sleep apnea in children and adolescents in Colombia according to the national health registry 2017-2021. PLoS One. 2022 Aug 31;17(8):e0273324.

5. Fernández-Ávila DG, Bernal-Macías S, Parra MJ, Rincón DN, Gutiérrez JM, Rosselli D. Prevalence of osteoporosis in Colombia: Data from the National Health Registry from 2012 to 2018. Reumatol Clin (Engl Ed). 2021 Dec;17(10):570-574.

6. Cifuentes-González C, Amaris-Martínez S, Reyes-Guanes J, Uribe-Reina P, de-la-Torre A. Incidence, prevalence, and demographic characteristics of ocular cicatricial pemphigoid in Colombia: data from the National Health Registry 2009-2019. Int J Ophthalmol. 2021 Nov 18;14(11):1765-1770.

7. Fernández-Ávila DG, Bernal-Macías S, Gutiérrez JM, Rincón DN, Rosselli D. Prevalence of systemic sclerosis in Colombia: Data from the National Health Registry 2012-2016. J Scleroderma Relat Disord. 2020 Jun;5(2):137-142.

8. León-Núñez LJ, Camero-Ramos G, Gutiérrez JM. Epidemiology of snakebites in Colombia (2008-2016). Rev Salud Publica (Bogota). 2020 May 1;22(3):280-287.

9. Fernández-Ávila DG, Bernal-Macías S, Rincón-Riaño DN, Gutiérrez Dávila JM, Rosselli D. Prevalence of systemic lupus erythematosus in Colombia: data from the national health registry 2012-2016. Lupus. 2019 Sep;28(10):1273-1278.

10. Fernández-Ávila DG, Bernal-Macías S, Rincón-Riaño DN, Gutiérrez JM, Rosselli D. Prevalence of polymyalgia rheumatica in Colombia: data from the national health registry 2012-2016. Rheumatol Int. 2019 Sep;39(9):1631-1635.